Pfizer and Genentech Duke it Out in Court over Herceptin Biosimilar Patents Post author:Sam Post published:November 21, 2017 Post category:BioPharma Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Source: BioSpace You Might Also Like How Bristol-Myers Squibb Went From Potential Mega-Acquirer to Vulnerable Mega-Target January 26, 2017 New Device Could Quickly Assess Brain Bleeding In Head Injuries, Reveals April 5, 2017 9 Reasons to Buy Pfizer in 2018 and 1 Big One Not To December 21, 2017
How Bristol-Myers Squibb Went From Potential Mega-Acquirer to Vulnerable Mega-Target January 26, 2017
